Retatrutide, a triple agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors, significantly reduced liver fat in a 24-week, randomized, double-blind, placebo-controlled trial (n=98) of participants with metabolic dysfunction-associated steatotic liver disease (MASLD). At 24 weeks, mean relative change from baseline in liver fat was -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg), and +0.3% (placebo) (all *P* < 0.001 vs. placebo). Reductions were associated with changes in body weight, abdominal fat, and metabolic measures.
Publisher
Nature Medicine
Published On
Jul 01, 2024
Authors
Arun J. Sanyal, Lee M. Kaplan, Juan P. Frias, Bram Brouwers, Qiwei Wu, Melissa K. Thomas, Charles Harris, Nanette C. Schloot, Yu Du, Kieren J. Mather, Axel Haupt, Mark L. Hartman
Tags
Retatrutide
liver fat
metabolic dysfunction
steatotic liver disease
clinical trial
Related Publications
Explore these studies to deepen your understanding of the subject.
